July 2001
LOBBYING FRONT
The wild calls for patients' rights at the House of Delegates meeting did not prevent the chief executive from suing the board of trustees.
DISEASE MANAGEMENT
Physicians are more likely to buy in if they see better outcomes — and financial rewards that go with them.
ONLINE MEDICINE
More vendors are turning to the Internet to expand the reach of programs. Cutting-edge technology helps patients help themselves.
PHARMACY BENEFIT
Pharmaceutical makers invest enormous sums in R&D – but they also reap enormous profits. States are impatient with the appearance that creates.
Peer-Reviewed
Q&A
The way to reduce errors in health care is to change systems, says this Harvard educator. Punishment encourages people to cover up.
Increasing demand for physicians and physician extenders is starting to strain the system. To a large extent, this is unexpected bitter fruit of managed care's labor.
Compensation Monitor
Editor’s Memo
Employer Update
Managed Care Outlook
Washington Watch
Follow us
Today's popular content
- The Challenge of Personalizing Health Care
- One Question
- How Doctors Are Paid Now, And Why It Has to Change
- What the Primary Care Physician Shortage Means for Health Plans
- Specialty Pharmacy Management Will Become More Intense
- Transdermal Patches Are More Than Skin Deep
- Inter-Rater Reliability Testing For Utilization Management Staff
- Disruptive Innovations That Will Change Your Life in Health Care
- Transparency Called Key To Uniting Cost Control, Quality Improvement
- A Modest, Not Satirical, Proposal For Assisted-Suicide Decisions
Recent blog posts
- SCOTUS and Manufacturing of Generics: Cry Havoc and Let Slip the Dogs of Litigation
- One Question
- Doc Execs Give Consumer Ratings Sites an ‘F’
- More Will Be Expected of Pharmacists
- Not Getting It the First Time
- What Changes are Coming for P&T Committees as a Result of the Affordable Care Act?
- Health Care Industry’s Moment of Truth Is Approaching
- Through the Looking Glass
- Physician Practices Hiring Care Coordinators
- Who Will Pay for High-Cost Biologics?
